NASH biomarkers market seen doubling by 2030 as liver disease testing expands

The non-alcoholic steatohepatitis biomarkers market is projected to rise from $1.68 billion in 2025 to $2.08 billion in 2026, with growth expected to continue to $4.6 billion by 2030. North America leads now, while Asia-Pacific is forecast to grow fastest as demand builds for non-invasive diagnostics, biomarker-driven trials and earlier disease detection.

Why it matters: - NASH biomarkers are becoming more important as liver disease, obesity and type 2 diabetes cases rise. - The market’s growth reflects demand for better diagnosis, monitoring and treatment selection without invasive procedures. - Biomarkers also matter for liver cancer care, where earlier detection and prognosis can improve clinical decisions.

What happened: - The Business Research Company released its Non-Alcoholic Steatohepatitis Biomarkers Global Market Report 2026. - The report values the market at $1.68 billion in 2025 and $2.08 billion in 2026. - The report projects the market will reach $4.6 billion by 2030. - North America was the largest regional market in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period.

The details: - The 2026 growth rate is projected at 23.2% year over year. - The forecast through 2030 implies a 22.0% CAGR. - Growth in 2026 is linked to rising metabolic disorders, including obesity and type 2 diabetes. - Expansion in liver disease research and wider availability of advanced diagnostic tests are also supporting demand. - Pharmaceutical companies are increasing their focus on therapies targeting NASH. - The report expects stronger investment in precision hepatology, non-invasive diagnostics, biomarker-focused clinical trials and personalized medicine. - The report also points to growing use of serum-based NASH biomarkers, artificial intelligence in biomarker analysis, companion diagnostics and early disease detection. - NASH is a liver condition marked by inflammation and damage caused by fat buildup in liver cells. - Biomarkers in NASH help assess liver damage, disease severity, disease activity and response to treatment. - Without proper detection and management, NASH can lead to cirrhosis and liver failure. - The report says the market benefits from the rising prevalence of liver cancer. - NASH biomarkers support early liver cancer detection, disease monitoring, treatment assessment, prognostic insight and lower use of invasive testing. - In July 2025, ecancer medical science projected new liver cancer cases would nearly double from 870,000 in 2022 to 1.52 million by 2050. - The same projection said liver cancer deaths would rise from 760,000 in 2022 to 1.37 million by 2050. - The journal tied that rise to population growth and aging, with the sharpest increases expected in Africa. - The report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The report also includes key technology and future trend analysis.

Between the lines: - The market is shifting from broad liver-disease testing toward more precise, non-invasive tools that can support both diagnosis and drug development. - The strong forecast suggests NASH biomarkers are moving from a niche research category to a larger commercial diagnostics segment. - The emphasis on Asia-Pacific signals that healthcare infrastructure and chronic disease burden are becoming major growth drivers outside traditional U.S. and European markets.

What's next: - The report expects continued expansion in clinical trials tied to biomarkers and in personalized medicine adoption. - Companies are likely to keep investing in AI-enabled analysis and companion diagnostics as NASH drug development advances. - Faster uptake of non-invasive testing could widen the market if early detection becomes a standard part of liver disease care.

The bottom line: - NASH biomarkers are emerging as a high-growth diagnostics market because they sit at the intersection of liver disease, cancer risk, non-invasive testing and precision medicine.